Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Advanced Accelerator Applications
To assess the incidence and nature of potential long-term safety outcomes in patients with unresectable or metastatic, well-differentiated, somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours. Retrospective and prospective data will be used.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
adult patients (fulfilling the definition of "age of majority" per local regulations),
with unresectable or metastatic, well-differentiated, somatostatin receptor positive GEP-NETs
and who were treated with Lutathera (regardless of the quantity and number of doses administered and whatever the reasons for ending).
You may not be if
Hypersensitivity to Lutathera (active substance or any of the excipients),
presence of established or suspected pregnancy or pregnancy not excluded,
presence of kidney failure with creatinine clearance \< 30 mL/min.
Clareo Health | Post-Authorization Long-Term Safety Study of LUTATHERA
